Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization
出版年份 2022 全文链接
标题
Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization
作者
关键词
-
出版物
Biomed Research International
Volume 2022, Issue -, Pages 1-13
出版商
Hindawi Limited
发表日期
2022-07-07
DOI
10.1155/2022/6253978
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
- (2022) Chenyi Luo et al. Frontiers in Oncology
- CD44 Targeted Nanomaterials for Treatment of Triple-Negative Breast Cancer
- (2021) Ghazal Nabil et al. Cancers
- Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
- (2021) Lisa Agnello et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer
- (2020) Gamze Guney Eskiler et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
- (2020) Manzoor Mir et al. CURRENT CANCER DRUG TARGETS
- Optimization of production parameters for fabrication of thymol-loaded chitosan nanoparticles
- (2020) M. Ali Çakır et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort
- (2019) Zubaidah Zakaria et al. OncoTargets and Therapy
- Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy
- (2019) Chunai Gong et al. JOURNAL OF NANOBIOTECHNOLOGY
- Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
- (2019) Hamdy A. Azim et al. Breast Journal
- Predicting drug release kinetics from nanocarriers inside dialysis bags
- (2019) Minzhi Yu et al. JOURNAL OF CONTROLLED RELEASE
- STAT3 as a promising chemoresistance biomarker associated with the CD44 +/high /CD24 -/low /ALDH + BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line
- (2018) Milene Pereira Moreira et al. EXPERIMENTAL CELL RESEARCH
- Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
- (2018) Yvonne W. S. Jauw et al. EJNMMI Research
- Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth
- (2017) Jingying Zheng et al. Theranostics
- Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis
- (2017) Wenzhe Li et al. Scientific Reports
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
- (2016) C. Willemien Menke-van der Houven van Oordt et al. Oncotarget
- Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters
- (2015) Brijesh Shah et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells
- (2014) Walhan Alshaer et al. BIOCONJUGATE CHEMISTRY
- Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)
- (2014) Fei Ma et al. CANCER LETTERS
- Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
- (2014) XINZHAO WANG et al. ONCOLOGY REPORTS
- Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
- (2014) J. J. Tao et al. Science Signaling
- The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method
- (2013) Mohsen Nabi-Meibodi et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Investigation of drop breakage and coalescence in the liquid–liquid system with nonionic surfactants Tween 20 and Tween 80
- (2012) Agata Bąk et al. CHEMICAL ENGINEERING SCIENCE
- Targeting EGFR in Triple Negative Breast Cancer
- (2012) Naoto T. Ueno et al. Journal of Cancer
- Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor
- (2011) Yinghuan Li et al. ADVANCED DRUG DELIVERY REVIEWS
- RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule
- (2011) Sarah Shigdar et al. CANCER SCIENCE
- Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design
- (2011) Xinsheng Peng et al. International Journal of Nanomedicine
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Development and Statistical Optimization of Solid Lipid Nanoparticles of Simvastatin by Using 23 Full-Factorial Design
- (2010) Mayank Shah et al. AAPS PHARMSCITECH
- Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
- (2010) Hiroshi Maeda BIOCONJUGATE CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started